Janus Henderson Group PLC Anavex Life Sciences Corp. Transaction History

Janus Henderson Group PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$4.55 - $6.75 $18 - $27	4 Added 0.01%	32,213 $163,000
Q4 2023 Feb 14, 2024	SELL	$5.04 - $9.95 $322 - $636	-64 Reduced 0.2%	32,209 $299,000
Q3 2023 Nov 14, 2023	BUY	$6.55 - $9.37 $52 - $74	8 Added 0.02%	32,273 $211,000
Q2 2023 Aug 14, 2023	SELL	$7.66 - $9.5 $191 - $237	-25 Reduced 0.08%	32,265 $262,000
Q1 2023 May 15, 2023	BUY	$8.32 - $11.75 $155,750 - $219,960	18,720 Added 137.95%	32,290 $276,000
Q3 2022 Nov 14, 2022	BUY	$8.9 - $12.86 $204 - $295	23 Added 0.17%	13,570 $140,000
Q2 2022 Aug 15, 2022	SELL	$7.31 - $12.84 $73 - $128	-10 Reduced 0.07%	13,547 $136,000
Q1 2022 May 16, 2022	BUY	$9.74 - $17.69 $132,045 - $239,823	13,557 New	13,557 $167,000

161

27.4M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $818M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.